Analysis of causation of Stevens Johnson Syndrome in a patient of rheumatoid arthritis with increased dose of methotrexate
|
|
- Tiffany Perkins
- 5 years ago
- Views:
Transcription
1 Original Research Article Analysis of causation of Stevens Johnson Syndrome in a patient of rheumatoid arthritis with increased dose of methotrexate Manab Nandy 1, Sangeeta De 2*, Mustafa Asad 2, Nirmal Polle 3 1 Associate Professor, Department of Pharmacology, Medical College, Kolkata, West Bengal, India 2Post Graduate Trainee, Department of Pharmacology, Medical College Kolkata, West Bengal, India 3Consultant AMRI Hospital, Kolkata, West Bengal, India * Corresponding author drsangieta2013@gmail.com International Archives of Integrated Medicine, Vol. 4, Issue 12, December, Copy right 2017, IAIM, All Rights Reserved. Available online athttp://iaimjournal.com/ ISSN: (P)ISSN: (O) Received on: Accepted on: Source of support: Nil Conflict of interest: None declared. How to cite this article: Manab Nandy, Sangeeta De, Mustafa Asad, Nirmal Polle. Analysis of causation of Stevens Johnson Syndrome in a patient of rheumatoid arthritis with increased dose of methotrexate. IAIM, 2017; 4(12): Abstract Rheumatoid arthritis (RA) is an autoimmune disease affecting about 1% of people, with the highest incidence between 40 and 70 years. Methotrexate is a folic acid antagonist that has good efficacy and safety in the treatment of RA. Methotrexate (MTX) and non-steroidal anti-inflammatory drugs are often concomitantly administered in clinical practice for the treatment of RA. In this case report 46 year old male patient, a known case of rheumatoid arthritis was admitted with history of knee joint pain and swelling. Methotrexate was initially started in a dose of 7.5 mg per week, dose was then increased to 15 mg per week. Six weeks later, the patient complained of oral ulcerations, erythematous, itchy and edematous rash on all four limbs and trunk. The patient was re-evaluated and was diagnosed with Stevens-Johnson syndrome. All the previous medications were stopped. The patient was treated with steroids, prophylactic antibiotics and antifungal drugs. The lesions started to heal after 5 days of hospitalization. Thus the treatment of Rheumatoid arthritis with methotrexate should be carefully considered due to its increased toxicity and risk of severe skin reactions. Key words Methotrexate, Stevens-Johnson syndrome, Increased dose. Page 132
2 Introduction Methotrexate (MTX) is a potent competitive inhibitor of dihydrofolatereductase (DHFR), a key enzyme in the generation of reduced folates crucial for the biosynthesis of purines and thymidylic acid. Methotrexate has good efficacy and safety in the treatment of Rheumatoid arthritis (RA). Stevens-Johnson syndrome (SJS) is a minor form of toxic epidermal necrolysis, with less than 10% body surface area (BSA) detachment. Stevens- Johnson syndrome is idiopathic in 25-50% of cases. Drugs and malignancies are most often implicated as the etiology in adults and elderly persons. Pediatric cases are related more often to infections [1]. SJS usually begins with fever, sore throat, and fatigue. Ulcers and other lesions begin to appear in the mucous membranes, almost always in the mouth and lips, but also in the genital and anal regions. Those in the mouth are usually extremely painful and reduce the patient's ability to eat or drink. Conjunctivitis of the eyes occurs in about 30% of children who develop SJS.A rash of round lesions about an inch across arises on the face, trunk, arms and legs, and soles of the feet, but usually not the scalp [2]. Materials and methods 46 year old male patient, a known case of rheumatoid arthritis was admitted with history of knee joint pain and swelling. Methotrexate was initially started in a dose of 7.5 mg per week, dose was then increased to 15 mg per week. The patient was also getting naproxen (500mg) concomitantly. Six weeks later, the patient complained of oral ulcerations, erythematous, itchy and edematous rash on all four limbs and trunk. The patient was re-evaluated and was diagnosed with Stevens-Johnson syndrome. The physical examination was remarkable for cutaneous involvement of all the four limbs and trunk (Figure - 1, 2). Erythematous and itchy rash were seen (Figure - 3, 4). Oral lesions were also seen. The vital signs recorded were as follows: temperature (axillary) ºC; pulse rate- 88/min; respiration rate - 18/min; blood pressure - 150/80 mmhg. Laboratory investigations revealed hemoglobin 8.9 g/dl, white blood cell count 8500 mm 3, platelet count 4,20,000 mm 3, serum creatinine 1.1 mg/dl, blood urea nitrogen 18 mg/dl, liver function test was normal. Blood and urine cultures were sterile. Chest X- ray and ultrasound abdomen was normal. Figure 1: The skin lesions in SJS. Figure 2: The skin lesions in SJS. Figure 3: The skin lesions in SJS. After the patient s assessment, consultations by a dermatologist were availed. The diagnosis of SJS was concurred. All the previous medications taken by the patient were discontinued. Apart from methotrexate, the previous medications included hydroxychloroquine 200 mg, folic acid 1 mg, pantoprazole 40 mg, naproxen 500 mg, leflunomide 20 mg. Page 133
3 Figure 4: The skin lesions in SJS. The patient was treated with steroids, prophylactic antibiotics and antifungal drugs. Anaemia was corrected. The lesions started to heal after 5 days of hospitalization. Results The diagnosis and management of severe cutaneous adverse drug reactions like SJS require meticulous recording of the case history of the patient. The etiology of SJS is not clear and could be due to drug induced immunological mechanism [3]. The most frequently involved groups of therapeutic agents cited in the literature are sulphonamides, anticonvulsants, nonsteroidal anti-inflammatory drugs and beta lactam antibiotics [4]. Although SJS is an immune mediated hypersensitivity reaction, it is debatable whether they are dose related or caused by drug-drug interaction, but in our case it is quite clear that it is the increased dose of methotrexate that caused the skin reaction. Methotrexate has 100,000 times greater affinity than folic acid for the dihydrofolatereductase enzyme [5]. This mechanism of methotrexate to reduce the tetrahydrofolate and attentuate the DNA synthesis in proliferating cells, makes it an ideal disease modifying agent for rheumatoid arthritis. Methotrexate is metabolized into a series of polyglutamate derivatives that increase linearly with the concentration and duration of exposure. Therefore, higher doses of methotrexate administered for prolonged duration can result in greater toxicity [6]. MTX is reversibly bound to albumin in plasma and can be displaced by other drugs that are administered simultaneously [7]. A recent Cochrane systematic review documented 17 publications on concurrent use of MTX and NSAIDs; however, none reported systemic adverse drug reactions or other major toxicity [8]. Previously in few patients skin ulcerations, necrosis, erosions of the psoriatic plaques and bullous acral erythema, have been reported as adverse effects of methotrexate [9, 10]. In a study, by Lawrence and Dahl, seven patients were treated with low dose of methotrexate and NSAIDs for psoriatic plaque and pre-existing dermatitis. Ulcerations occurred in four patients, who received long term MTX therapy, either after increasing the MTX dosage or taking NSAIDs; the skin ulcerations healed after reducing MTX dose in these patients [10]. In our patient, MTX was initially started in a dose of 7.5 mg per week, dose was then increased to 15 mg per week. The patient was also getting naproxen (500mg) concomitantly. Six weeks later, the patient complained of oral ulcerations, erythematous, itchy and edematous rash on all four limbs and trunk. This could be possibly due to the reason that naproxen oral increases levels of methotrexate sodium by decreasing renal clearance. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. NSAIDs may reduce tubular secretion of methotrexate and enhance MTX toxicity [11]. Methotrexate being an anti-folate molecule may arrest normal epidermal cell proliferation at high doses. Thus, SJS may be a dose dependent adverse drug reaction in susceptible individuals. We used Naranjo Adverse Drug Reaction Probability Scale to calculate the probability of methotrexate in the causation of SJS [12]. In our case, we got a score of 5 (Table - 1) which clearly tells the probable causal relation between the occurrence of SJS after the higher dose of MTX administered. Page 134
4 Table 1: Scoring of probability of methotrexate in causation of SJS by Naranjo Adverse Drug Reaction Probability Scale. Questions Yes No Do not score know 1. Are there previous conclusive reports on this reaction? Did the adverse event appear after the suspected drug was administered? 3. Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? 4. Did the adverse event reappear when the drug was re administered? 5.Are there alternative causes (other than the drug) that could on their own have caused the reaction? 6. Did the reaction reappear when a placebo was given? Was the drug detected in blood (or other fluids) in concentrations known to be toxic? 0 8. Was the reaction more severe when the dose was increased or less severe when the dose was decreased? Did the patient have a similar reaction to the same or similar drugs in any previous exposure? Was the adverse event confirmed by any objective evidence? Total score 5 Discussion and Conclusion The treatment of RA with methotrexate should be carefully considered due to its increased toxicity and risk of severe skin reactions. Higher doses of methotrexate administered for prolonged duration can result in SJS. The SJS caused by medication with MTX was clinically diagnosed, and the methotrexate was discontinued in our patient due to adverse reaction. Our case demonstrates that the SJS can occur following 15mg weekly dose of methotrexate in RA. The syndrome was not present until before increasing the dose of MTX. These arguments provide a strong support for a causal relationship between the SJS and higher dose methotrexate administration in our case. Thus the treatment of RA with methotrexate should be carefully considered due to its increased toxicity and risk of severe skin reactions. References overview. (Last seen on 20/10/2017) E2%80%93Johnson_syndrome#Signs_ and_symptoms.(last seen on 20/10/2017) 3. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnsons syndrome. Orphanet J Rare Dis., 2010; 5(39): Jezierska-Krupa B, Hyla-Klekot L. Toksycznanekrolizanaskörka a zespótstevensa-johnsona (Polish). Ped Pol., 1996; 60: Weinstein GD, Goldfaden G, Frost P. Methotrexate mechanism of action on DNA synthesis in psoriasis. Arch Dermatol., 1971; 123: Madani TA, Zafad S, Harif M, Quessar A, et al. Methotrexate-induced toxic epidermal necrolysis: a case report. Page 135
5 International Journal of Medicine and Medical Science, 2009; 1(4): Maeda A, Tsuruoka S, Ushijima K, Kanai Y, Endou H, Saito K, et al. Drug interaction between celecoxib and methotrexate in organic anion transporter 3 transfected renal cells and in rats in vivo. Eur J Pharmacol., 2010; 640(1-3): Colebatch AN, Marks JL, van der Heijde DM, Edwards CJ. Safety of non-steroidal anti-inflammatory drug and/or paracetamol in people receiving methotrexate for inflammatory arthritis: A Cochrane Systematic Review. J Rheumatol Suppl., 2012; 90: Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am AcadDermatol., 1988; 19: Lawrence CM, Dahl MG. Two patterns of skin ulceration induced by methotrexate in patients with psoriasis. J Am AcadDermatol., 1984; 11(6): seen on 20/10/2017) 12. Naranjo CA. A method for estimating the probability of adverse drug reactions. ClinPharmacolTher., 1981; 30: Page 136
NEOFEN 60 mg suppository
PACKAGE LEAFLET: INFORMATION FOR THE USER NEOFEN 60 mg suppository IBUPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationEMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - PANCYTOPENIA AND SERIOUS SKIN REACTIONS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 October 1999 EMEA/31637/99 EMEA PUBLIC STATEMENT ON LEFLUNOMIDE (ARAVA) - PANCYTOPENIA AND
More informationEtoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets , Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets 23.5.2016, Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary Etoricoxib STADA 30 mg film-coated
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Osteoarthritis Osteoarthritis is the most common type of joint disease. It represents a group of conditions that result in changes
More informationXATMEP (methotrexate) oral solution
XATMEP (methotrexate) oral solution Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen
PACKAGE LEAFLET: INFORMATION FOR THE USER EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking Easofen Max Strength Tablets because it contains
More informationREGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES. R e g i S C A R PATIENT'S DATA. Age country of birth
REGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES R e g i S C A R PATIENT'S DATA Initials of the patient date of birth Age country of birth Gender male female
More informationMedical Management of Rheumatoid Arthritis (RA)
Medical Management of Rheumatoid Arthritis (RA) Dr Lee-Suan Teh Rheumatologist Royal Blackburn Hospital Educational objectives ABC Appreciate the epidemiology of RA Be able to diagnosis of RA Competent
More informationInflammatory arthritis Shared Decision Making
Inflammatory arthritis Shared Decision Making DMARDs El Miedany et al. Ann Rheum Dis 74(Suppl2): 1002 DOI: 10.1136/annrheumdis-2015-eular.1410 www.rheumatology4u.com Copyrights reserved Contents 1 2 3
More informationBACTRIM tablets PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1 WHAT BACTRIM IS AND WHAT IT IS USED FOR
PACKAGE LEAFLET: INFORMATION FOR THE USER BACTRIM tablets CO-TRIMOXAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationMethotrexate supplementation with folate
P ford residence southampton, ny Methotrexate supplementation with folate The good news: These side effects can often be shortcircuited by taking a folic acid supplement. Folic acid is the synthetic form
More informationPackage leaflet: Information for the user. Floxapen 250 mg & 500 mg Capsules. Flucloxacillin
Package leaflet: Information for the user Floxapen 250 mg & 500 mg Capsules Flucloxacillin Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationElements for a Public Summary. Overview of Disease Epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of Disease Epidemiology Toxicity of Folic acid antagonists Despite having a low frequency of major toxicity, low dose Methotrexate (MTX, folic acid antagonist)
More informationEfficacy of Concomitant Use of PUVA and Methotrexate in Disease Clearance Time in Plaque Type Psoriasis
Efficacy of Concomitant Use of PUVA and Methotrexate in Disease Clearance Time in Plaque Type Psoriasis T. Shehzad ( Departments of Dermatology Naval Hospital PNS Shifa, Karachi. ) N. R. Dar ( Departments
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) METHOTREXATE ORION 2.5 MG & 10 MG TABLET (METHOTREXATE DISODIUM) DATE: , VERSION 1.
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) METHOTREXATE ORION 2.5 MG & 10 MG TABLET (METHOTREXATE DISODIUM) DATE: 23-6-2016, VERSION 1.2 VI.2 Elements for a Public Summary Methotrexate is indicated for:
More informationDrug Allergy A Guide to Diagnosis and Management
Drug Allergy A Guide to Diagnosis and Management (Version 1 April 2015 updated April 2018) Author: Jed Hewitt Chief Pharmacist, Governance & Professional Practice Date of Preparation: April 2015 Updated:
More informationPackage leaflet: Information for the user. Piperacillin/Tazobactam Actavis 4 g / 0.5 g powder for solution for infusion. piperacillin / tazobactam
Package leaflet: Information for the user Piperacillin/Tazobactam Actavis 2 g / 0.25 g powder for solution for infusion Piperacillin/Tazobactam Actavis 4 g / 0.5 g powder for solution for infusion piperacillin
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationAspirin with methotrexate
P ford residence southampton, ny Aspirin with methotrexate Aspirin reference guide for safe and effective use from the American Society of Health- System Pharmacists (AHFS DI). Aspirin, also known as acetylsalicylic
More informationRABEPRAZOL 10mg and 20mg Gastro-resistant Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet
More informationEU RISK MANAGEMENT PLAN (EU RMP)
EU RISK MANAGEMENT PLAN (EU RMP) Active substance(s) (INN or common name): Esomeprazole Pharmaco-therapeutic group (ATC Code): A02B C05 Name of Marketing Authorisation Holder or Applicant: Strength and
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationACUTE ANNULAR URTICARIA IN A CHILD
The West London Medical Journal 2013 Vol 5 No 2 pp 1-5 ACUTE ANNULAR URTICARIA IN A CHILD Aaron Yon Dayse Fernandes Michelle Pike Jodi Newcombe Colin Michie 1. ABSTRACT Urticarial skin rashes have a range
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Lung cancer is one of the most common types of cancer in European men and women. There are two main types of lung cancer: small
More informationOntario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions
Ontario Public Drug Programs Inflectra (infliximab) Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationUsing ENBREL to Treat Rheumatoid and Psoriatic Arthritis
Using ENBREL to Treat Rheumatoid and Psoriatic Arthritis Writing White Papers class Bellevue Community College TABLE OF CONTENTS TABLE OF CONTENTS...2 OVERVIEW...3 RHEUMATOID ARTHRITIS... 3 JUVENILE RHEUMATOID
More informationSarcoidosis Case. Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA. WASOG: educational material
Sarcoidosis Case Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA WASOG: educational material Sarcoidosis Case patient is a Caucasian male age 46 was diagnosed
More informationAction Naproxen sodium, the active principle of Naproxan, has been developed as an analgesic because it is more rapidly absorbed than Naproxen.
NAPROXAN Composition Each tablet contains Naproxen sodium 275 mg. Tablets Action Naproxen sodium, the active principle of Naproxan, has been developed as an analgesic because it is more rapidly absorbed
More informationWhat is Enbrel? Key features
What is Enbrel? Enbrel (also known by its generic name etanercept) is a biologic medication approved in April 2004 by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe
More informationManaging Methotrexate Toxicity A Case Report
CASE REPORT International Healthcare Research Journal 2017;1(1):28-32. QR CODE Managing Methotrexate Toxicity A Case Report ANDLA SHARMA 1 A B S T R A C T Methotrexate, a folic acid analogue is being used
More informationSULFASALAZIN 500mg enteric-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SULFASALAZIN 500mg enteric-coated tablets SULFASALAZINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a
More information- Active rheumatoid arthritis in adult patients where treatment with disease modifying antirheumatic drugs (DMARD) is indicated.
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) TREXAN 25 MG/ML, SOLUTION FOR INJECTION, PRE-FILLED SYRINGE ORION CORPORATION DATE: 12-01-2015, VERSION 1.2 VI.2 Elements for a Public Summary Methotrexate
More informationAzathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS
Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Only valid for adult patients Azathioprine must be at a dose of at least
More informationNew product information wording Extracts from PRAC recommendations on signals
12 October 2017 EMA/PRAC/610988/2017 Pharmacovigilance Risk Assessment Committee (PRAC) New product information wording Extracts from PRAC recommendations on signals Adopted at the 25-29 September 2017
More informationDERMATOLOGY FOR THE INTERNIST. Emilie Chow, MD 8/2017
DERMATOLOGY FOR THE INTERNIST Emilie Chow, MD 8/2017 GOALS ALL SLIDES ARE FOCUSED ON CLINICAL CASES IN THE FORM OF QUESTIONS AND MKSAP COVERED TOPICS USING POLLEV.COM Reference for material is MKSAP 17
More informationDr. Venkateswari. R. Dr. Janani Sankar s unit Kanchi Kamakoti CHILDS Trust Hospital
Dr. Venkateswari. R. Dr. Janani Sankar s unit Kanchi Kamakoti CHILDS Trust Hospital Acknowledgements: KKCTH Dr. Ramkumar Consultant Dermatologist Dr. Ramprakash Consultant Ophthalmologist Dr. Prasad Manne
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Drug: Methotrexate Introduction Indication: Licensed: Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic arthritis, severe psoriatic arthritis, mild to moderate
More informationProducts available Methotrexate tablets 2.5mg ONLY (Methotrexate tablets 10mg are NOT recommended as per NPSA guidance 5 ).
Methotrexate Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Drug Allergy. These podcasts are designed to give medical students an overview of key topics in pediatrics. The audio
More informationRISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.
RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion
More informationCASE-BASED SMALL GROUP DISCUSSION
MHD I, Session 11, Student Copy Page 1 CASE-BASED SMALL GROUP DISCUSSION MHD I SESSION 11 Renal Block Acid- Base Disorders November 7, 2016 MHD I, Session 11, Student Copy Page 2 Case #1 Cc: I have had
More informationUSTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE
Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA 36187 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of psoriatic arthritis (PsA)
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Methotrexate 2.5mg Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Methotrexate 2.5mg Tablets Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this
More informationCASE REPORTS. Jorida Kuçaj 1, Sotiraq Lako 1, Etleva Gjoshe 1, Teuta Dedej 2. Abstract
CASE REPORTS ALBANIAN MEDICAL JOURNAL methotrexate therapy and hyperleukocytosis after filgrastim administration to a patient with subacute cutaneous Lupus Erythematosus Jorida Kuçaj 1, Sotiraq Lako 1,
More informationKevzara (sarilumab) NEW PRODUCT SLIDESHOW
Kevzara (sarilumab) NEW PRODUCT SLIDESHOW Introduction Brand name: Kevzara Generic name: Sarilumab Pharmacological class: Interleukin-6 antagonist Strength and Formulation: 150mg/1.14mL, 200mg/1.14mL;
More informationUse of abatacept in rheumatoid arthritis - patient information
Practical management of patients receiving abatacept 1 Use of abatacept in rheumatoid arthritis - patient information Evidence-based Medicine Official Recommendations Expert opinion Key points 1. Abatacept
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationPronaxen 250 mg tablet OTC , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Pronaxen 250 mg tablet OTC 25.9.2015, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Pronaxen 250 mg is indicated for
More informationEmergency Dermatology Dr Melissa Barkham
Emergency Dermatology Dr Melissa Barkham Spotlight Seminar 30 th September 2010 Why is this important? Urgent recognition and treatment of dermatologic emergencies can be life saving and prevent long term
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Areloger 7.5 mg Tablets Areloger 15 mg Tablets meloxicam
PACKAGE LEAFLET: INFORMATION FOR THE USER Areloger 7.5 mg Tablets Areloger 15 mg Tablets meloxicam Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationMethotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
More informationRashes Not To Be Missed In Children
May 2016 Rashes Not To Be Missed In Children Dr Chan Yuin Chew Dermatologist Dermatology Associates Gleneagles Medical Centre Scope of presentation Focus on rashes May lead to significant morbidity if
More informationCASE-BASED SMALL GROUP DISCUSSION MHD II
MHD II, Session 11, Student Copy Page 1 CASE-BASED SMALL GROUP DISCUSSION MHD II Session 11 April 11, 2016 STUDENT COPY MHD II, Session 11, Student Copy Page 2 CASE HISTORY 1 Chief complaint: Our baby
More informationRecalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University
Recalcitrant Warty Erythroderma With Severe Pruritus Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Gil Yosipovitch,
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date:
Clinical Policy: (Taltz) Reference Number: ERX.SPA.122 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Deferasirox is a medicine used to treat chronic iron overload (an excess of iron in the body). Chronic iron overload is a condition
More informationStevens Johnson Syndrome: How Diagnosis Impacts Disease Course
Southern Adventist Univeristy KnowledgeExchange@Southern Graduate Research Projects Nursing 12-4-2015 Stevens Johnson Syndrome: How Diagnosis Impacts Disease Course Sharon K. Hart Southern Adventist University,
More informationSystemic examination
PROLONGED FEVER IN AN ADOLESCENT BOY Dr.Praveena Lionel, DNB PG, Dr.Kannan (HOD) Railway Hospital, Perambur History 11 yrs old adolescent boy was admitted with c/o Fever -1 wk Myalgia -1 wk Arthralgia
More informationPATIENT INFORMATION LEAFLET Cyclophosphamide 50 mg Tablets Cyclophosphamide monohydrate
PATIENT INFORMATION LEAFLET Cyclophosphamide 50 mg Tablets Cyclophosphamide monohydrate Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read
More informationPHM142 Autoimmune Disorders + Idiosyncratic Drug Reactions
PHM142 Autoimmune Disorders + Idiosyncratic Drug Reactions 1 Autoimmune Disorders Auto-reactivity: low physiological levels (e.g. tolerance) vs. pathogenic levels 80+ types of autoimmune diseases affect
More informationTOFACITINIB PATIENT INFORMATION ON. (Brand name: Xeljanz ) What is tofacitinib? Important things to remember
PATIENT INFORMATION ON TOFACITINIB (Brand name: Xeljanz ) This information sheet has been produced by the Australian Rheumatology Association to help you understand the medicine that has been prescribed
More informationEmergency Dermatology. Emergency Dermatology
Emergency Dermatology These are rapidly progressive skin conditions and some are potentially lifethreatening. Early recognition is important to implement prompt supportive care and therapy. Some are drug
More informationSiklos (hydroxyurea) NEW PRODUCT SLIDESHOW
Siklos (hydroxyurea) NEW PRODUCT SLIDESHOW Introduction Brand name: Siklos Generic name: Hydroxyurea Pharmacological class: Antimetabolite Strength and Formulation: 100mg, 1000mg+; tabs; +triple-scored
More informationAppendix 1: Frequently Asked Questions
Appendix 1: Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added to the Ontario Drug Benefit (ODB) Formulary
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationAmjevita (adalimumab-atto)
*- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled
More informationTHE USE OF ANTIMETABOLITES IN THE TREATMENT OF PSORIASIS
189 SINGAPORE MEDICAL JOURNAL. Vol. 7, No. 3. September, 1966. THE USE OF ANTIMETABOLITES IN THE TREATMENT OF PSORIASIS By Chan Wan Hor, M.B.B.S., and Khoo Oon Teik, M.D., M.R.C.P.E., F.R.F.P.S. (Medical
More informationClinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationBreast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer
Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Indication: Neoadjuvant therapy for high risk and fit breast cancer patients suitable for
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Enbrel (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More information4 2 Osteoarthritis 1
Osteoarthritis 1 Osteoarthritis ( OA) Osteoarthritis is a chronic disease and the most common of all rheumatological disorders. It particularly affects individuals over the age of 65 years. The prevalence
More informationINDICATIONS ACULAR 0,4% ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.
Page 1 SCHEDULING STATUS Schedule 4 PROPRIETARY NAME (and dosage form) ACULAR 0,4% COMPOSITION ACULAR 0,4% ophthalmic solution contains: Ketorolac tromethamine: 4 mg/ml Preservative: Benzalkonium chloride
More informationBlack italics are the narration or interviews as recorded on the film. Blue are the slides and text in the film
HIV Paediatric case 14 - Shukran This is the story of 8 year old Shukran. He is an only child who now lives with his father. He s come into hospital with a rash. The skin is blistering and peeling off.
More informationEMEA PUBLIC STATEMENT ON PARECOXIB SODIUM (Dynastat/Rayzon/Xapit) RISK OF SERIOUS HYPERSENSITIVITY AND SKIN REACTIONS
The European Agency for the Evaluation of Medicinal Products Post-authorisation evaluation of medicines for human use London, 22 October 2002 EMEA/25175/02 EMEA PUBLIC STATEMENT ON PARECOXIB SODIUM (Dynastat/Rayzon/Xapit)
More informationThe chemical name of acyclovir, USP is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6Hpurin-6-one; it has the following structural formula:
Acyclovir Ointment, USP 5% DESCRIPTION Acyclovir, USP, is a synthetic nucleoside analogue active against herpes viruses. Acyclovir ointment, USP 5% is a formulation for topical administration. Each gram
More informationGreater Manchester Interface Prescribing Group Shared Care Template
Greater Manchester Interface Prescribing Group Shared Care Template Shared Care Guideline for Oral Methotrexate for Rheumatological Conditions Author(s)/Originator(s): (please state author name and department)
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationDERMATOLOGICAL EMERGENCIES. DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE
DERMATOLOGICAL EMERGENCIES DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE Dermatological Emergencies INFECTIONS ERYTHRODERMA DRUG ERUPTIONS STEVENS-JOHNSON
More informationPackage Leaflet: Information for the User Zyloric 100 mg and 300 mg tablets allopurinol
Package Leaflet: Information for the User Zyloric 100 mg and 300 mg tablets allopurinol Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read
More informationDuration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1
Leflunomide Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti Rheumatic
More informationCutaneous Drug Reactions
Cutaneous Drug Reactions Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada Copyright 2017 by Sea Courses
More informationParadoxial Safety Signals from Biologics
Paradoxial Safety Signals from Biologics Christopher Ritchlin, MD, MPH Professor of Medicine Director, Translational Immunology Research Center University of Rochester Medical Center Rochester, NY Disclosures
More informationFuture of Pediatrics: Blisters, Hives and Other Tales from the Emergency Room June 14 th, 2016
A. Yasmine Kirkorian MD Assistant Professor of Dermatology & Pediatrics Children s National Health System George Washington University School of Medicine & Health Sciences Future of Pediatrics: Blisters,
More informationCutaneous manifestations and systemic correlation in patients with lupus erythematosus and its subsets: a study of 40 cases
International Journal of Research in Dermatology Mahajan R et al. Int J Res Dermatol. 2018 Nov;4(4):479-483 http://www.ijord.com Original Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20183407
More informationShared Care Protocol Oral methotrexate 2.5mg tablets in dermatology/gastroenterology/rheumatology patients
Shared Care Protocol Oral methotrexate 2.5mg tablets in dermatology/gastroenterology/rheumatology patients Specialist Details Name: Patient Identifier (please include NHS number as minimum) Location: Telephone
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. Today s Date: Date of HSCT for which this form is being completed:
Juvenile Idiopathic Arthritis Pre-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic, allogeneic,
More informationAdrenocorticotropic hormone gel in patients with refractory rheumatoid arthritis: a case series
International Journal of Clinical Rheumatology For reprint orders, please contact: reprints@futuremedicine.com Adrenocorticotropic hormone gel in patients with refractory rheumatoid arthritis: a case series
More informationERROR CORRECTION FORM
Juvenile Idiopathic Arthritis Pre-HSCT Data Sequence Number: Registry Use Only Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic, allogeneic, syngeneic unrelated related
More informationA Retrospective Study of Spectrum of Nevirapine Induced Cutaneous Drug Reactions in HIV Positive Patients
Journal of US-China Medical Science 12 (2015) 85-89 doi: 10.17265/1548-6648/2015.02.008 D DAVID PUBLISHING A Retrospective Study of Spectrum of Nevirapine Induced Cutaneous Drug Reactions in HIV Positive
More informationSummary of the risk management plan (RMP) for Pemetrexed Actavis (pemetrexed)
EMA/58503/2016 Summary of the risk management plan (RMP) for Pemetrexed Actavis (pemetrexed) This is a summary of the risk management plan (RMP) for Pemetrexed Actavis, which details the measures to be
More information10/25/2018. Autoimmunity and how to treat it. Disclosure. Why do we get autoimmunity? James Verbsky MD/PhD Pediatric Rheumatology/Immunology
Autoimmunity and how to treat it James Verbsky MD/PhD Pediatric Rheumatology/Immunology Disclosure None I will mention drug names and some brand names but I have no financial interest or any other ties
More informationTNF Receptor Associated Periodic Syndrome (TRAPS)
https://www.printo.it/pediatric-rheumatology/gb/intro TNF Receptor Associated Periodic Syndrome (TRAPS) Version of 2016 1. WHAT IS TRAPS 1.1 What is it? TRAPS is an inflammatory disease characterised by
More informationHerbal and homeopathic products, often considered natural and non-toxic, can also cause adverse drug reactions.
Idiosyncratic and potentially serious cutaneous adverse drug reactions (CADRs), although relatively rare, account for significant morbidity and mortality. RANNAKOE J LEHLOENYA, BSc, MB ChB, FCDerm (SA)
More informationLeflunomide APOTEX Tablets Leflunomide
Leflunomide APOTEX Tablets Leflunomide Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet This leaflet answers some common questions about leflunomide.
More informationPackage leaflet: Information for the patient. Melox 10 mg/ml solution for injection meloxicam
Package leaflet: Information for the patient Melox 10 mg/ml solution for injection meloxicam Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationSYSTEMIC THERAPY OF MODERATE AND SEVERE PSORIASIS WITH METHOTREXATE
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 SYSTEMIC THERAPY OF MODERATE AND SEVERE PSORIASIS WITH METHOTREXATE M. FRÎNCU 1 A. OANŢĂ 1 Abstract:
More informationMEDICATION PROTOCOL FOR PHYSICIANS
Mary Pack Arthritis Program 895 West 10th Avenue Vancouver, B.C. V5Z 1L7 MEDICATION PROTOCOL FOR PHYSICIANS Generic Name: Brand Name: Indications Contraindications SODIUM AUROTHIOMALATE MYOCHRYSINE Rheumatoid
More information